![Richard Colvin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Richard Colvin formerly worked at Novartis, Inc., as Executive Director-Translational Medicine from 2014 to 2018 and bluebird bio, Inc., as VP & Head-Severe Genetic Diseases Clinical R&D from 2020 to 2021.
Dr. Colvin received his undergraduate degree from Cornell University and doctorate degree from Duke University School of Medicine.
| Sociétés | Poste | Fin |
|---|---|---|
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Corporate Officer/Principal | 01/10/2018 |
| GENETIX BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco, CA. | Health Technology |
bluebird bio, Inc.
 bluebird bio, Inc. BiotechnologyHealth Technology Develops genetic therapies based on blood stem cells | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University School of Medicine
 Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
